Affiliation:
1. Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, Poland
Abstract
The development of therapies for advanced gastric cancer (GC) has made significant progress over the past few years. The identification of new molecules and molecular targets is expanding our understanding of the disease’s intricate nature. The end of the classical oncology era, which relied on well-studied chemotherapeutic agents, is giving rise to novel and unexplored challenges, which will cause a significant transformation of the current oncological knowledge in the next few years. The integration of established clinically effective regimens in additional studies will be crucial in managing these innovative aspects of GC. This study aims to present an in-depth and comprehensive review of the clinical advancements in targeted therapy and immunotherapy for advanced GC.
Reference192 articles.
1. Epidemiology of gastric cancer;Crew;World J. Gastroenterol.,2006
2. Lauren classification and individualized chemotherapy in gastric cancer;Ma;Oncol. Lett.,2016
3. NcicancerStats (2023, August 23). Cancer of the Stomach–Cancer Stat Facts: @NCICancerStats, Available online: https://seer.cancer.gov/statfacts/html/stomach.html.
4. Global Cancer Incidence and Mortality Rates and Trends—An Update;Torre;Cancer Epidemiol. Biomark. Prev.,2016
5. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease study 2017;Collaborators;Lancet Gastroenterol. Hepatol.,2020